← All Crispr Therapeutics AG filings

Crispr Therapeutics AG 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CRSP
Crispr Therapeutics AG
10-K: CRISPR Therapeutics Reports Increased Losses Amidst Pipeline Progress
CRISPR Therapeutics AG reported a significant increase in net loss for 2025, driven by higher collaboration expenses, despite advancing its gene-editing pipeline and securing key approvals for CASGEVY.
NASDAQ
CRSP
Crispr Therapeutics AG
10-K: CRISPR Therapeutics Reports 2024 Results, Highlights Progress in Gene-Editing Therapies
CRISPR Therapeutics' 2024 10-K filing highlights the company's advancements in gene-based medicines, including the commercialization of CASGEVY and progress in CAR T and in vivo programs, while acknowledging ongoing financial losses and risks.
NASDAQ
CRSP
Crispr Therapeutics AG
10-K: CRISPR Therapeutics AG Details Share Structure and Financial Health in 10-K Filing
CRISPR Therapeutics AG's 10-K filing provides a comprehensive overview of its share structure, financial performance, and strategic direction, highlighting its advancements in gene editing technology.